{
    "organizations": [],
    "uuid": "e9fccf22bb20020529c313b822be34677b13037f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-intellipharmaceutics-received-noti/brief-intellipharmaceutics-received-notice-from-nasdaq-hearings-panel-idUSFWN1ST0PB",
    "ord_in_thread": 0,
    "title": "BRIEF-Intellipharmaceutics Received Notice From Nasdaq Hearings Panel",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 22 (Reuters) - Intellipharmaceutics International Inc :\n* INTELLIPHARMACEUTICS INTERNATIONAL - RECEIVED NOTICE FROM NASDAQ HEARINGS PANEL GRANTING REQUEST FOR CONTINUED LISTING UNTIL SEPT 28, 2018 Source text: ( bit.ly/2rZpVwr ) Further company coverage:\n ",
    "published": "2018-05-23T04:25:00.000+03:00",
    "crawled": "2018-05-23T15:17:54.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "intellipharmaceutics",
        "international",
        "inc",
        "intellipharmaceutics",
        "international",
        "received",
        "notice",
        "nasdaq",
        "hearing",
        "panel",
        "granting",
        "request",
        "continued",
        "listing",
        "sept",
        "source",
        "text",
        "company",
        "coverage"
    ]
}